

Exporting from Cortellis



Exporting from Cortellis

How to download data from Cortellis to different formats.

1 Enter your keyword and click **Search**.

2 Apply the desired filters.

3 Click **Results list** under the **Export** button.

Cortellis Search "rheumatoid arthritis" Assistant Search

Drugs Deals Clinical trials Companies Patents More

1,997 drug results Show search query

Generate competitive landscape Analytics Export Save and Alert

Drugs with... Status Indication Technology All filters Columns

☐ Drug name	Highest status overall	Other drug name	Active company	Active indication	Date first launched	Technology
☐ CIGB-814	Phase 2 Clinical	CIGB-814 ESAR-814 Hsp60 peptide (juvenile idiop...	Shandong Lukang Pharmaceu... Center for Genetic Engineerin...	Rheumatoid arthritis	N/A Hsp 60 modulator	Biological Peptide Subcutaneo
☐ oxaprozin	Registered	Coxanto oxaprozin	Solubiomix LLC(US)(Pharma)	Juvenile rheumatoid arthritis Osteoarthritis	N/A N/A	Capsule form Small molec

Results list Report Table Charts

Note: Similar steps can be followed to export other report types (deals, companies, etc).

Export from Cortellis

Export a predefined set of columns.

Export results

Choose document type

✓ Excel (xls)

SD file

BizInt

☒ Formatted Excel

☐ Unformatted Excel

☐ ISIS for Excel

Choose document format

☒ Results table

☐ Results table + additional fields ⓘ

☐ Current development status results

☐ Complete current and historical development status results

Export files

16 results in 1 files

↓ Results 1 - 16

Export more available columns (patent, first launch data, etc).

Include all phases of development the drug is currently at (may create multiple rows per drug in your file).

Include current and historical phases of development (may create multiple rows per drug in your file).

Export from Cortellis

Optional:
Export to alternative types of software.

Select desired format.

Export results

Choose document type

✓ Excel (xls)

SD file

BizInt

☒ Formatted Excel

☐ Unformatted Excel

☐ ISIS for Excel

Choose document format

☒ Results table

☐ Results table + additional fields ⓘ

☐ Current development status results

☐ Complete current and historical development status results

Export files

16 results in 1 files

↓

Results 1 - 16

Confirm your format and layout.

Once you have finished selecting your preferences, click **Results** to export your file (s).

Export from Cortellis

Samples

Current development status results - Unformatted Excel

	A	E	F	G	I	J
	Drug Name	Companies	Indications	Development Status	Country/Territory	Date
1						
15	imeroprubart	Immunovant Sciences GmbH	Rheumatoid arthritis	Phase 3 Clinical	Puerto Rico	06-Feb-2025
16	imeroprubart	Immunovant Sciences GmbH	Rheumatoid arthritis	Phase 3 Clinical	US	06-Feb-2025
17	canakinumab biosimilar (adult onset Stills disease)	Generium JSC	Adult onset Stills disease	Phase 3 Clinical	Russian Federation	29-Jun-2023
18	gofikicept	R-Pharm US LLC	Adult onset Stills disease	Phase 3 Clinical	Russian Federation	06-Apr-2026

Navigate back to any of these drugs in Cortellis by clicking the linked drug name.

Results table additional fields - Formatted Excel

		BC	BD	BE
Drug Name	First Paragraph of Summary	Development Status (Current) (Company : Country/Territory : Status : Indication : Date)	Development Status (History) (Company : Country/Territory : Status : Indication : Date)	Drug Development Phase (Indication : Phase : Country/Territory)
canakinumab biosimilar (adult onset Stills disease). Generium JSC	Generium JSC is developing GNR-086, a biosimilar version of canakinumab , for the potential treatment of adult onset Stills disease [3000539], [3575403]. In June 2023, a phase III trial in adult onset Stills disease was initiated [3000539].	Generium JSC: Russian Federation: Phase 3 Clinical: Adult onset Stills disease: 29-Jun-2023	Generium JSC: Russian Federation: Phase 1 Clinical: Adult onset Stills disease: 27-Jun-2023	Adult onset Stills disease: Phase 3 Clinical: Russian Federation
gofikicept	R-Pharm and its subsidiary R-Pharm US is developing gofikicept (RPH-104), a recombinant, heterodimeric fusion protein containing IL-1R1 and part of the IL-1R accessory protein, acts as a soluble trap for IL-1 alpha and IL-1 beta, for the potential sc treatment of Behcet's disease, familial Mediterranean fever (FMF), gout , idiopathic recurrent pericarditis and SARS-CoV-2 infection (COVID-19), adult-onset Still's disease (AOSD) [2263080], [1732281], [1654700], [2141390], [2187096], [2257507], [2198252], [3503489], [4459689]. The company is also investigating the drug for the potential treatment of Schnitzler syndromeand	R-Pharm US LLC: Russian Federation: Phase 3 Clinical: Adult onset Stills disease: 06-Apr-2026 R-Pharm: Russian Federation: Phase 3 Clinical: Adult onset Stills disease: 06-Apr-2026	R-Pharm: Russian Federation: Discovery: Familial Mediterranean fever: 12-Jan-2015 R-Pharm: Turkey: Phase 1 Clinical: Familial Mediterranean fever: 31-Jan-2016 R-Pharm: Russian Federation: Preclinical: Pericarditis: 10-Oct-2019 R-Pharm: Russian Federation: Preclinical: Coronavirus disease 19 infection: 06-Apr-2020 R-Pharm: Russian Federation: Preclinical: Myocardial infarction: 09-Jul-2020 R-Pharm: Russian Federation: Preclinical: Adult onset Stills disease: 25-Mar-2022 R-Pharm US LLC: Russian Federation: Preclinical: Adult onset Stills disease: 25-Mar-2022	Adult onset Stills disease: Phase 3 Clinical: Russian Federation Adult onset Stills disease: Phase 3 Clinical: Russian Federation